SCHEMBL170140

SCHEMBL170140

Cn1c(=O)oc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.57
HPGD P15428 3/20 0.57
TSHR P16473 2/20 0.57
USP2 O75604 1/20 0.57
ALDH1A1 P00352 5/20 0.56
NPSR1 Q6W5P4 2/20 0.56
LMNA P02545 1/20 0.53
MIF P14174 1/20 0.50
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
GAA P10253 1/20 0.49
IDO1 P14902 1/20 0.49
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29455598 1.00 MAPK1 (0.57) MAPK1HPGDTSHRUSP2ALDH1A1
Hydrochloric Acid SCHEMBL29709689 0.98 MAPK1 (0.55) MAPK1HPGDTSHRUSP2ALDH1A1
Trifluoroacetic Acid SCHEMBL15390334 0.85 ALDH1A1 (0.54) MAPK1HPGDTSHRUSP2ALDH1A1
SCHEMBL29455650 0.84 ALDH1A1 (0.45) MAPK1HPGDTSHRUSP2ALDH1A1
SCHEMBL11049346 0.81 MAPT (0.43) MAPK1HPGDTSHRUSP2ALDH1A1
SCHEMBL29511366 0.75 GPR3 (0.52) HPGDTSHRALDH1A1LMNAPKM
SCHEMBL159458 0.75 GPR3 (0.52) HPGDTSHRALDH1A1LMNAPKM
SCHEMBL12049010 0.75 MAPK1 (0.53) MAPK1HPGDTSHRUSP2ALDH1A1
SCHEMBL171826 0.75 KDM4E (0.48) MAPK1HPGDTSHRUSP2ALDH1A1
SCHEMBL9210565 0.75 ALDH1A1 (0.72) MAPK1HPGDTSHRUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018033525-A1 AGONISTS OR PARTIAL AGONISTS OF THE HISTAMINE SITE OF THE NMDA RECEPTOR FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-02-22 WO claimed
EP-2280766-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS CytoPathfinder, Inc. (JP) 2011-02-09 EP claimed
WO-2010129843-A1 DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS CYTOPATHFINDER, INC. (JP) 2010-11-11 WO claimed
WO-2009076512-A1 CARBOXAMIDΞ COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS EPIX DELAWARE, INC. (US) 2009-06-18 WO claimed
EP-1601335-B1 MEANS AND METHOD FOR THE SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBRES WELLA AG (DE) 2008-03-19 EP claimed
US-7291183-B2 Agent and method for dyeing keratin fibers WELLA AG (DE) 2007-11-06 US claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO claimed
EP-1599179-B1 AGENT AND METHOD FOR DYEING KERATIN FIBRES WELLA AG (DE) 2006-10-11 EP claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
US-20060162096-A1 Means and method for the simultaneous bleaching and dyeing of keratin fibres HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) 2006-07-27 US claimed
US-20060010616-A1 Agent and method for dyeing keratin fibers Wella GmbH (DE) 2006-01-19 US claimed
EP-1601335-A1 MEANS AND METHOD FOR THE SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBRES Wella Aktiengesellschaft (DE) 2005-12-07 EP claimed
WO-2004078152-A1 MEANS AND METHOD FOR THE SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBRES WELLA AKTIENGESELLSCHAFT (DE) 2004-09-16 WO claimed
EP-1359908-A1 QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-11-12 EP claimed
WO-2002056882-A1 QUINOLINES AND NITROGENATED DERIVAIVE THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-25 WO claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-4658034-A Process for the preparation of 2,6-dichlorobenzoxazole HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-14 US disclosed
US-4621084-A CARDIOTONIC, ANTIULCER FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-11-04 US disclosed
EP-0120589-A1 Imidazo-heterocyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060162096-A1 Means and method for the simultaneous bleaching and dyeing of keratin fibres KRT18, GPX4, NOX4 MAPK1 654/4885HPGD 1038/4885TSHR 2086/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH MAPK1 4010/4885HPGD 815/4885TSHR 400/4885
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 MAPK1 3183/4885HPGD 1825/4885TSHR 4292/4885
US-20060010616-A1 Agent and method for dyeing keratin fibers KRT18, KIT, MKI67 MAPK1 179/4885HPGD 755/4885TSHR 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.